Long-term (≥15 years) Follow-up of Percutaneous Coronary Intervention of Unprotected Left Main (From the GRAVITY Registry).


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 10 2021
Historique:
received: 28 03 2021
revised: 04 06 2021
accepted: 14 06 2021
pubmed: 31 7 2021
medline: 21 9 2021
entrez: 30 7 2021
Statut: ppublish

Résumé

Long term survival and its determinants after Percutaneous Coronary Intervention (PCI) on Unprotected Left Main Coronary Artery (ULMCA) remain to be appraised. In 9 European Centers 470 consecutive patients performing PCI on ULMCA between 2002 and 2005 were retrospectively enrolled. Survival from all cause and cardiovascular (CV) death were the primary end points, while their predictors at multivariate analysis the secondary ones. Among the overall cohort 81.5% of patients were male and mean age was 66 ± 12 years. After 15 years (IQR 13 to 16), 223 patients (47%) died, 81 (17.2%) due to CV etiology. At multivariable analysis, older age (HR 1.06, 95%CI 1.02 to 1.11), LVEF < 35% (HR 2.97, 95%CI 1.24 to 7.15) and number of vessels treated during the index PCI (HR 1.75, 95%CI 1.12 to 2.72) were related to all-cause mortality, while only LVEF <35% (HR 4.71, 95%CI 1.90 to 11.66) to CV death. Repeated PCI on ULMCA occurred in 91 (28%) patients during the course of follow up and did not significantly impact on freedom from all-cause or CV mortality. In conclusion, in a large, unselected population treated with PCI on ULMCA, 47% died after 15 years, 17% due to CV causes. Age, number of vessels treated during index PCI and depressed LVEF increased risk of all cause death, while re-PCI on ULMCA did not impact survival.

Identifiants

pubmed: 34325877
pii: S0002-9149(21)00566-X
doi: 10.1016/j.amjcard.2021.06.008
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

72-78

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Fabrizio D'Ascenzo (F)

Department of Medical Science, Città Della Salute e della Scienza, Division of Cardiology, Turin, Italy. Electronic address: fabrizio.dascenzo@gmail.com.

Edoardo Elia (E)

Department of Medical Science, Città Della Salute e della Scienza, Division of Cardiology, Turin, Italy.

Giorgio Marengo (G)

Department of Medical Science, Città Della Salute e della Scienza, Division of Cardiology, Turin, Italy.

Wojciech Wańha (W)

Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland.

R González Ferreiro (R)

Department of Cardiology, University Hospital Alvaro Cunqueiro, Vigo, Spain.

Alessandra Truffa (A)

Division of Cardiology, Ospedale di Asti, Italy.

Daniela Trabattoni (D)

Division of Cardiology, Ospedale Monzino, Milan, Italy.

Filippo Figini (F)

Division of Cardiology, Pederzoli Hospital-Peschiera del Garda, Verona, Italy.

Roberto Verardi (R)

Department of Medical Science, Città Della Salute e della Scienza, Division of Cardiology, Turin, Italy; U.O.C. Cardiologia, Ospedale Maggiore, Bologna, Italy.

G Di Palma (G)

Cardiovascular Research Team, San Carlo Clinic, Milan, Italy.

Fabio Infusino (F)

Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Umberto I Hospital, Sapienza University of Rome, Rome, Italy.

Carlo Pivato (C)

Cardio Center, Humanitas Clinical and Research Center IRCCS, Rozzano-Milan, Italy.

Andrzej Ochała (A)

Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland.

Pierluigi Omedè (P)

Department of Medical Science, Città Della Salute e della Scienza, Division of Cardiology, Turin, Italy.

Marek Milewski (M)

Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland.

Roi Estevez (R)

Department of Cardiology, University Hospital Alvaro Cunqueiro, Vigo, Spain.

S Raporeiras Roubin (S)

Department of Cardiology, University Hospital Alvaro Cunqueiro, Vigo, Spain.

O De Filippo (O)

Department of Medical Science, Città Della Salute e della Scienza, Division of Cardiology, Turin, Italy.

Federico Conrotto (F)

Department of Medical Science, Città Della Salute e della Scienza, Division of Cardiology, Turin, Italy.

Antonio Montefusco (A)

Department of Medical Science, Città Della Salute e della Scienza, Division of Cardiology, Turin, Italy.

Sebastiano Gili (S)

Division of Cardiology, Ospedale Monzino, Milan, Italy.

Bernardo Cortese (B)

Cardiovascular Research Team, San Carlo Clinic, Milan, Italy.

Veronica Dusi (V)

Department of Molecular Medicine, Section of Cardiology, University of Pavia, Pavia, Italy.

Guglielmo Gallone (G)

Department of Medical Science, Città Della Salute e della Scienza, Division of Cardiology, Turin, Italy.

Roberto Manfredi (R)

Department of Medical Science, Città Della Salute e della Scienza, Division of Cardiology, Turin, Italy.

Massimo Mancone (M)

Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Umberto I Hospital, Sapienza University of Rome, Rome, Italy.

G Biondi Zoccai (G)

Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, Rome, Italy; Mediterranea Cardiocentro, Naples, Italy.

Gianni Casella (G)

U.O.C. Cardiologia, Ospedale Maggiore, Bologna, Italy.

Christian Templin (C)

Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland.

Giulio Stefanini (G)

Cardio Center, Humanitas Clinical and Research Center IRCCS, Rozzano-Milan, Italy.

Wojciech Wojakowski (W)

Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland.

Imad Sheiban (I)

Division of Cardiology, Pederzoli Hospital-Peschiera del Garda, Verona, Italy.

G M De Ferrari (GM)

Department of Medical Science, Città Della Salute e della Scienza, Division of Cardiology, Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH